UBS Group’s Benitec Biopharma BNTC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.23M | Buy |
115,819
+17,472
| +18% | +$202K | ﹤0.01% | 5384 |
|
|
2025
Q4 | $1.32M | Sell |
98,347
-1,594
| -2% | -$22K | ﹤0.01% | 5334 |
|
|
2025
Q3 | $1.4M | Buy |
99,941
+82,057
| +459% | +$1.05M | ﹤0.01% | 5286 |
|
|
2025
Q2 | $209K | Buy |
17,884
+7,872
| +79% | +$110K | ﹤0.01% | 6692 |
|
|
2025
Q1 | $130K | Buy |
10,012
+4,999
| +100% | +$60.5K | ﹤0.01% | 6838 |
|
|
2024
Q4 | $63.3K | Buy |
5,013
+3,089
| +161% | +$33.4K | ﹤0.01% | 7154 |
|
|
2024
Q3 | $17.7K | Sell |
1,924
-108
| -5% | -$966 | ﹤0.01% | 7440 |
|
|
2024
Q2 | $14.2K | Buy |
2,032
+1,520
| +297% | +$11.2K | ﹤0.01% | 7527 |
|
|
2024
Q1 | $2.69K | Sell |
512
-110
| -18% | -$422 | ﹤0.01% | 7847 |
|
|
2023
Q4 | $2.01K | Buy |
622
+513
| +471% | +$1.71K | ﹤0.01% | 8179 |
|
|
2023
Q3 | $329 | Buy |
109
+89
| +445% | +$277 | ﹤0.01% | 8573 |
|
|
2023
Q2 | $82 | Hold |
20
| – | – | ﹤0.01% | 8540 |
|
|
2023
Q1 | $73 | Sell |
20
-55
| -73% | -$224 | ﹤0.01% | 9287 |
|
|
2022
Q4 | $217 | Sell |
75
-1,612
| -96% | -$5.46K | ﹤0.01% | 10307 |
|
|
2022
Q3 | $11K | Buy |
1,687
+986
| +141% | +$12.5K | ﹤0.01% | 8275 |
|
|
2022
Q2 | $13K | Buy |
701
+681
| +3,405% | +$15.8K | ﹤0.01% | 7496 |
|
|
2022
Q1 | $1K | Sell |
20
-163
| -89% | -$6.76K | ﹤0.01% | 9844 |
|
|
2021
Q4 | $8K | Buy |
183
+121
| +195% | +$6.76K | ﹤0.01% | 9019 |
|
|
2021
Q3 | $4K | Buy |
62
+44
| +244% | +$2.89K | ﹤0.01% | 8626 |
|
|
2021
Q2 | $1K | Sell |
18
-67
| -79% | -$5.24K | ﹤0.01% | 9124 |
|
|
2021
Q1 | $8K | Buy |
85
+67
| +372% | +$4.55K | ﹤0.01% | 8072 |
|
|
2020
Q4 | $1K | Hold |
18
| – | – | ﹤0.01% | 8196 |
|
|
2020
Q3 | $2K | Sell |
18
-59
| -77% | -$7.12K | ﹤0.01% | 7633 |
|
|
2020
Q2 | $10K | Buy |
+77
| New | +$10.4K | ﹤0.01% | 7003 |
|
|
2020
Q1 | – | Sell |
-42
| Closed | -$6K | – | 7967 |
|
|
2019
Q4 | $6K | Buy |
42
+18
| +75% | +$2.71K | ﹤0.01% | 7501 |
|
|
2019
Q3 | $4K | Buy |
24
+2
| +9% | +$368 | ﹤0.01% | 7536 |
|
|
2019
Q2 | $4K | Buy |
22
+16
| +267% | +$6.49K | ﹤0.01% | 7437 |
|
|
2019
Q1 | $3K | Buy |
6
+3
| +100% | +$1.29K | ﹤0.01% | 7323 |
|
|
2018
Q4 | $1K | Sell |
3
-5
| -63% | -$2.76K | ﹤0.01% | 7879 |
|
|
2018
Q3 | $5K | Sell |
8
-7
| -47% | -$4.78K | ﹤0.01% | 7472 |
|
|
2018
Q2 | $8K | Buy |
15
+1
| +7% | +$676 | ﹤0.01% | 7250 |
|
|
2018
Q1 | $11K | Sell |
14
-3
| -18% | -$2.53K | ﹤0.01% | 6801 |
|
|
2017
Q4 | $13K | Hold |
17
| – | – | ﹤0.01% | 6853 |
|
|
2017
Q3 | $10K | Buy |
17
+11
| +183% | +$5.87K | ﹤0.01% | 6881 |
|
|
2017
Q2 | $2K | Buy |
6
+5
| +500% | +$3.16K | ﹤0.01% | 7364 |
|
|
2017
Q1 | $1K | Hold |
1
| – | – | ﹤0.01% | 7405 |
|
|
2016
Q4 | $0 | Hold |
1
| – | – | ﹤0.01% | 7771 |
|
|
2016
Q3 | $0 | Sell |
1
-7
| -88% | -$2.9K | ﹤0.01% | 7675 |
|
|
2016
Q2 | $2K | Buy |
+8
| New | +$3.17K | ﹤0.01% | 7419 |
|
Other funds holding BNTC
SCM
RCM
NCM
VCM
IAM
UBS Group's BNTC Position: Q1 2026 in Review
UBS Group increased its Benitec Biopharma (BNTC) stake by 18% in Q1 2026, buying an estimated $202K and bringing the position to 115,819 shares worth $1.23M. The position accounts for ﹤0.01% of the portfolio, ranked #5384.
UBS Group first reported a position in BNTC in Q2 2016 and has held it in 39 quarters since. The position peaked at $1.4M in Q3 2025. 88 funds tracked by Wall St. Rank hold BNTC as of Q1 2026.
- UBS Group held 115,819 shares of Benitec Biopharma worth $1.23M as of Q1 2026.
- UBS Group bought 17,472 Benitec Biopharma shares in Q1 2026, an estimated $202K.
- Benitec Biopharma made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #5384 holding.
- UBS Group first reported a position in Benitec Biopharma in Q2 2016 and has held it in 39 quarters since.
- UBS Group's Benitec Biopharma position peaked at $1.4M in Q3 2025.
- 88 funds tracked by Wall St. Rank held Benitec Biopharma as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.